Tom Sumner

List of Publications by Year
in descending order

23 papers	1,048 citations	567281 15 h-index	642732 23 g-index
23 all docs	23 docs citations	23 times ranked	1609 citing authors

#	Article	IF	Citations
1	Cost-effectiveness of routine adolescent vaccination with an M72/AS01E-like tuberculosis vaccine in South Africa and India. Nature Communications, 2022, 13, 602.	12.8	13
2	Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. Lancet Infectious Diseases, The, 2021, 21, 354-365.	9.1	84
3	Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study. The Lancet Global Health, 2021, 9, e841-e853.	6.3	34
4	The impact of blood transcriptomic biomarker targeted tuberculosis preventive therapy in people living with HIV: a mathematical modelling study. BMC Medicine, 2021, 19, 252.	5.5	4
5	Potential impact of tuberculosis vaccines in China, South Africa, and India. Science Translational Medicine, 2020, 12, .	12.4	42
6	The predicted impact of tuberculosis preventive therapy: the importance of disease progression assumptions. BMC Infectious Diseases, 2020, 20, 880.	2.9	6
7	Informing Balanced Investment in Services and Health Systems: A Case Study of Priority Setting for Tuberculosis Interventions in South Africa. Value in Health, 2020, 23, 1462-1469.	0.3	5
8	The potential impact of COVID-19-related disruption on tuberculosis burden. European Respiratory Journal, 2020, 56, 2001718.	6.7	166
9	Should NICE reconsider the 2016 UK guidelines on TB contact tracing? A cost-effectiveness analysis of contact investigations in London. Thorax, 2019, 74, 185-193.	5.6	5
10	Potential population level impact on tuberculosis incidence of using an mRNA expression signature correlate-of-risk test to target tuberculosis preventive therapy. Scientific Reports, 2019, 9, 11126.	3.3	13
11	Application of provincial data in mathematical modelling to inform sub-national tuberculosis program decision-making in South Africa. PLoS ONE, 2019, 14, e0209320.	2.5	9
12	Age-targeted tuberculosis vaccination in China and implications for vaccine development: a modelling study. The Lancet Global Health, 2019, 7, e209-e218.	6.3	45
13	Transmission events revealed in tuberculosis contact investigations in London. Scientific Reports, 2018, 8, 6676.	3.3	4
14	A Bayesian Approach to Understanding Sex Differences in Tuberculosis Disease Burden. American Journal of Epidemiology, 2018, 187, 2431-2438.	3.4	26
15	Empirical estimation of resource constraints for use in model-based economic evaluation: an example of TB services in South Africa. Cost Effectiveness and Resource Allocation, 2018, 16, 27.	1.5	20
16	An evaluation of tuberculosis contact investigations against national standards. Thorax, 2017, 72, 736-745.	5.6	27
17	Catastrophic costs potentially averted by tuberculosis control in India and South Africa: a modelling study. The Lancet Global Health, 2017, 5, e1123-e1132.	6.3	41
18	Post-treatment effect of isoniazid preventive therapy on tuberculosis incidence in HIV-infected individuals on antiretroviral therapy. Aids, 2016, 30, 1279-1286.	2.2	17

#	Article	IF	Citations
19	Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines. Human Vaccines and Immunotherapeutics, 2016, 12, 2813-2832.	3.3	78
20	Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. The Lancet Global Health, 2016, 4, e806-e815.	6.3	138
21	Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. The Lancet Global Health, 2016, 4, e816-e826.	6.3	69
22	Ability of preventive therapy to cure latent Mycobacterium tuberculosis infection in HIV-infected individuals in high-burden settings. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5325-5330.	7.1	49
23	Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15520-15525.	7.1	153